These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28864212)

  • 1. 14-O-Methylmorphine: A Novel Selective Mu-Opioid Receptor Agonist with High Efficacy and Affinity.
    Zádor F; Balogh M; Váradi A; Zádori ZS; Király K; Szűcs E; Varga B; Lázár B; Hosztafi S; Riba P; Benyhe S; Fürst S; Al-Khrasani M
    Eur J Pharmacol; 2017 Nov; 814():264-273. PubMed ID: 28864212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel µ-opioid receptor ligand with high in vitro and in vivo agonist efficacy.
    Lacko E; Varadi A; Rapavi R; Zador F; Riba P; Benyhe S; Borsodi A; Hosztafi S; Timar J; Noszal B; Furst S; Al-Khrasani M
    Curr Med Chem; 2012; 19(27):4699-707. PubMed ID: 22934777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
    Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
    Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of In Vivo and In Vitro Opioid Effects of Newly Synthesized 14-Methoxycodeine-6-
    Zádor F; Mohammadzadeh A; Balogh M; Zádori ZS; Király K; Barsi S; Galambos AR; László SB; Hutka B; Váradi A; Hosztafi S; Riba P; Benyhe S; Fürst S; Al-Khrasani M
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32192229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral antinociceptive efficacy and potency of a novel opioid compound 14-O-MeM6SU in comparison to known peptide and non-peptide opioid agonists in a rat model of inflammatory pain.
    Khalefa BI; Mousa SA; Shaqura M; Lackó E; Hosztafi S; Riba P; Schäfer M; Ferdinandy P; Fürst S; Al-Khrasani M
    Eur J Pharmacol; 2013 Aug; 713(1-3):54-7. PubMed ID: 23665110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology.
    Zádor F; Király K; Váradi A; Balogh M; Fehér Á; Kocsis D; Erdei AI; Lackó E; Zádori ZS; Hosztafi S; Noszál B; Riba P; Benyhe S; Fürst S; Al-Khrasani M
    Eur J Pharmacol; 2017 Aug; 809():111-121. PubMed ID: 28502630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
    Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
    Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
    Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
    Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
    Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
    Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
    Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new potent analgesic agent with reduced liability to produce morphine tolerance.
    Kiraly K; Caputi FF; Hanuska A; Kató E; Balogh M; Köles L; Palmisano M; Riba P; Hosztafi S; Romualdi P; Candeletti S; Ferdinandy P; Fürst S; Al-Khrasani M
    Brain Res Bull; 2015 Aug; 117():32-8. PubMed ID: 26235542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
    Peckham EM; Traynor JR
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1195-201. PubMed ID: 16291875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
    Gengo PJ; Pettit HO; O'Neill SJ; Wei K; McNutt R; Bishop MJ; Chang KJ
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1221-6. PubMed ID: 14534368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
    Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
    Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Morphine Analogs Produce Peripheral Antinociception within a Certain Dose Range of Their Systemic Administration.
    Lackó E; Riba P; Giricz Z; Váradi A; Cornic L; Balogh M; Király K; Csekő K; Mousa SA; Hosztafi S; Schäfer M; Zádori ZS; Helyes Z; Ferdinandy P; Fürst S; Al-Khrasani M
    J Pharmacol Exp Ther; 2016 Oct; 359(1):171-81. PubMed ID: 27435180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
    Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
    Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.